Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (9): 899-904.doi: 10.3969/j.issn.1000-6621.2021.09.008
• Original Articles • Previous Articles Next Articles
WU Guo-lan, GAO Jing-tao, CHEN Xiao-hong(), CHEN Li-zhou, WENG Li-zhen, GUO Zhi-ping, CHEN Xiu-ping, LIN Jian-dong, CHEN Su-xia, GAO Meng-qiu(), LIU Yu-hong
Received:
2021-07-15
Online:
2021-09-10
Published:
2021-09-07
Contact:
CHEN Xiao-hong,GAO Meng-qiu
E-mail:cxhong6886@126.com;gaomqwdm@aliyun.com
WU Guo-lan, GAO Jing-tao, CHEN Xiao-hong, CHEN Li-zhou, WENG Li-zhen, GUO Zhi-ping, CHEN Xiu-ping, LIN Jian-dong, CHEN Su-xia, GAO Meng-qiu, LIU Yu-hong. Short-term effectiveness and safety of a regimen containing bedaquiline in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2021, 43(9): 899-904. doi: 10.3969/j.issn.1000-6621.2021.09.008
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.09.008
患者 编号 | 性 别 | 年龄 (岁) | 病史 (年) | 治疗史 (月) | 病灶范围 (肺野个数) | 治疗前/后 空洞个数 | 治疗前痰 涂片菌量 | 耐药类型 | 并发症 |
---|---|---|---|---|---|---|---|---|---|
FZ01 | 男 | 48 | 11 | 57 | 6(右肺毁损) | 4/3 | ++++ | XDR-TB | 糖尿病 |
FZ02 | 女 | 36 | 2 | 13 | 5 | 1/0 | + | XDR-TB | 无 |
FZ03 | 男 | 27 | 7 | 11 | 6 | 5/3 | ++++ | pre-XDR-TB | 低体质量,支气管结核 |
FZ04 | 男 | 42 | 8 | 30 | 6(左肺毁损) | 5/4 | ++ | XDR-TB | 糖尿病,胸壁结核 |
FZ05 | 女 | 56 | 3 | 21 | 6(左肺毁损) | 4/2 | +++ | pre-XDR-TB | 高血压 |
FZ06 | 男 | 50 | 5 | 27 | 6 | 4/3 | ++++ | XDR-TB | 糖尿病,尘肺 |
FZ07 | 女 | 62 | 4 | 22 | 5 | 2/2 | ++ | XDR-TB | 支气管结核 |
FZ08 | 女 | 33 | 3 | 17 | 5 | 1/0 | -- | pre-XDR-TB | 淋巴结结核 |
FZ09 | 女 | 40 | 2 | 12 | 5 | 2/1 | + | pre-XDR-TB | 支气管结核 |
FZ10 | 男 | 56 | 5 | 15 | 6(右上肺毁损) | 5/3 | + | XDR-TB | 支气管扩张,尘肺 |
FZ11 | 男 | 32 | 8 | 25 | 6 | 4/2 | + | MDR-TB | 低体质量,支气管扩张 |
FZ12 | 男 | 38 | 1 | 2 | 6 | 0/0 | ++ | MDR-TB | 支气管结核 |
FZ13 | 女 | 55 | 4 | 15 | 4 | 2/1 | ++ | pre-XDR-TB | 支气管结核,支气管扩张 |
FZ14 | 男 | 51 | 2 | 3 | 3 | 0/0 | +++ | MDR-TB | 糖尿病 |
FZ15 | 男 | 67 | 3 | 16 | 5 | 1/1 | + | MDR-TB | 支气管结核 |
FZ16 | 男 | 26 | 2 | 10 | 4 | 0/0 | ++ | pre-XDR-TB | 无 |
患者编号 | 治疗方案 |
---|---|
FZ01 | 6Lzd-Cfz-Cs-Pa-Bdq/12Lzd-Cfz-Cs-Pa |
FZ02 | 6Lzd-Mfx-Cs-Pto-Z-Bdq/12Lzd-Mfx-Cs-Z-Pto |
FZ03 | 6Lzd-Cfz-Cs-Pa-Bdq/12Lzd-Cfz-Cs-Pa |
FZ04 | 6Lzd-Cs-Pa-Pto-Bdq/18Lzd-Cs-Pa-Pto |
FZ05 | 6Lzd-Mfx-Cs-Am-Pa-Bdq/12Lzd-Mfx-Cs-Pa |
FZ06 | 6Mfx-Lzd-Cfz-Cs-Bdq/18Mfx-Lzd-Cfz-Cs |
FZ07 | 6Mfx-Lzd-Cfz-Cs-Bdq/14Mfx-Lzd-Cfz-Cs |
FZ08 | 6Lzd-Cs-Am-Z-Pa-Bdq/12Lzd-Cs-Z-Pa |
FZ09 | 6Mfx-Lzd-Cs-Z-Pto-Bdq/12Mfx-Lzd-Cs-Z-Pto |
FZ10 | 6Mfx-Lzd-Cfz-Cs-Cm-Bdq/12Mfx-Lzd-Cfz-Cs |
FZ11 | 6Mfx-Lzd-Cs-Pto-Cm-Bdq/12Mfx-Lzd-Cs-Pto |
FZ12 | 6Lfx-Cs-Pto-Z-E-Bdq/12Lfx-Cs-Pto-Z-E |
FZ13 | 6Lzd-Cs-Pto-Pa-Bdq/14Lzd-Cs-Pto-Pa |
FZ14 | 6Lzd-Lfx-Cs-E-Bdq/14Lfx-Cs-Pto-Z-E |
FZ15 | 6Lzd-Lfx-Cs-Pto-Bdq/12Lzd-Lfx-Cs-Pto |
FZ16 | 6Lzd-Cs-Pto-Cfz-E-Am-Bdq/12Lzd-Cs-Pto-Cfz-E |
检测时间 | QTc间期[ms,M(Q1,Q3)] | Z值 | P值 |
---|---|---|---|
基线 | 412.50(398.25,420.75) | - | - |
治疗2周 | 414.00(405.00,426.75) | -0.569 | 0.569 |
治疗4周 | 419.50(402.00,434.50) | -1.242 | 0.214 |
治疗8周 | 410.50(398.25,421.25) | -0.078 | 0.938 |
治疗12周 | 421.50(409.50,434.75) | -2.198 | 0.028 |
治疗16周 | 424.50(413.75,432.25) | -2.096 | 0.036 |
治疗20周 | 421.50(409.50,434.75) | -1.965 | 0.049 |
治疗24周 | 424.00(414.00,435.25) | -2.406 | 0.016 |
[1] |
中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015, 37(5):421-469. doi: 10.3969/j.issn.1000-6521.2015.05.001.
doi: 10.3969/j.issn.1000-6521.2015.05.001 |
[2] |
Dheda K, Gumbo T, Gandhi NR, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med, 2014, 2(4):321-338. doi: 10.1016/S2213-2600(14)70031-1.
doi: 10.1016/S2213-2600(14)70031-1 URL |
[3] |
Field SK. Bedaquiline for the treatment multidrug-resistant tuberculosis:great promise or disappointment? Ther Adv Chronic Dis, 2015, 6(4):170-184. doi: 10.1177/2040622315582325.
doi: 10.1177/2040622315582325 URL |
[4] |
厉娟, 聂理会, 唐神结. 贝达喹啉抗结核作用及研究进展. 中华医学杂志, 2015, 95(16):1275-1277. doi: 10.3/cma.j.issn.0376-2491.2015.16.023.
doi: 10.3/cma.j.issn.0376-2491.2015.16.023 |
[5] | 姚岚, 唐神结. WHO 2014年版《耐药结核病规划管理指南伙伴手册》解读之四《贝达喹啉在治疗耐多药结核病的应用》. 中国防痨杂志, 2015, 34(5):534-536. |
[6] | World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva:World Health Organization, 2019. |
[7] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001 |
[8] |
中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识. 中华结核和呼吸杂志, 2018, 41(6):461-466. doi: 10.3760/cma.j.issn.1001-0939.2018.06.005.
doi: 10.3760/cma.j.issn.1001-0939.2018.06.005 |
[9] |
中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019, 42(10):733-749. doi: 10.3760/cma.j.issn.1001-0939.2019.10.006.
doi: 10.3760/cma.j.issn.1001-0939.2019.10.006 |
[10] |
singh P, Kumari R, Lal R. Bedaquiline:Fallible Hope Against Drug Resistant Tuberculosis. Indian J Microbiol, 2017, 57(4):371-377. doi: 10.1007/s12088-017-0674-0.
doi: 10.1007/s12088-017-0674-0 URL |
[11] |
Gao M, Gao J, Xie L, et al. Early outcome and study of beda-quiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect, 2021, 27(4):597-602. doi: 10.1016/j.cmi.2020.06.004.
doi: 10.1016/j.cmi.2020.06.004 URL |
[12] |
BorisovSE, Dheda K, Enwerem M, et al. Effectiveness andsafety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J, 2017, 49(5):1700387. doi: 10.1183/13993003.00387-2017.
doi: 10.1183/13993003.00387-2017 URL |
[13] |
Olaru ID, Heyckendorf J, Andres S, et al. Bedaquiline_based treatment regimen for multidrug-resistant tuberculosis. Eur Respir J, 2017, 49(5):1700742. doi: 10.1183/13993003.00742-2017.
doi: 10.1183/13993003.00742-2017 URL |
[14] |
Mukherjee A, Lodha R, Kabra SK. Current therapies for the treatment of multidrug-resistant tuberculosis in children in India. Expert Opin Pharmacother, 2017, 18(15):1595-1606. doi: 10.1080/14656566.2017.1373090.
doi: 10.1080/14656566.2017.1373090 pmid: 28847228 |
[15] |
Achar J, Hewison C, Cavalheiro AP, et al. Off-labeluse of Bedaquiline in children and adolescents with multidrug-resistant tuberculosis. Emerg Infect Dis, 2017, 23(10):1711-1713. doi: 10.3201/eid2310.170303.
doi: 10.3201/eid2310.170303 URL |
[16] |
Tadolini M, Garcia-Prats AJ, D’Ambrosio L, et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis:early experiences and challenges. Eur Respir J, 2016, 48(3):938-943. doi: 10.1183/13993003.00705-2016.
doi: 10.1183/13993003.00705-2016 pmid: 27338197 |
[17] |
Postema PG, Wilde AA. The measurement of the QT interval. Curr Cardiol Rev, 2014, 10(3):287-294. doi: 10.2174/1573403x10666140514103612.
doi: 10.2174/1573403x10666140514103612 pmid: 24827793 |
[18] |
谢莉, 高静韬, 马丽萍, 等. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响. 中国防痨杂志, 2020, 42(7):687-694. doi: 10.3969/j.issn.1000-6621.2020.07.009.
doi: 10.3969/j.issn.1000-6621.2020.07.009 |
[19] |
时正雨, 吴桂辉, 黄涛, 等. 含贝达喹啉方案治疗耐多药/广泛耐药结核病的24周单组观察性研究. 中国防痨杂志, 2021, 43(5):487-494. doi: 10.3969/j.issn.1000-6621.2021.05.014.
doi: 10.3969/j.issn.1000-6621.2021.05.014 |
[1] | DING Cai-hong, XIONG Yu, WANG Qing, GAO Xu-sheng, HAO Yan. Study on the early efficacy and safety of the regimen containing bedaquiline in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 893-898. |
[2] | YAO Rong, LU Yu. Research and progress of early bactericidal activity of anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 724-728. |
[3] | LI Ren-zhong, RUAN Yun-zhou, LI Yu-hong. Interpretation of the new definition of extensive drug-resistant tuberculosis defined by World Health Organization [J]. Chinese Journal of Antituberculosis, 2021, 43(6): 539-541. |
[4] | WANG Lu, XUE Zhong-tan, WANG Yu-feng, SHANG Yuan-yuan, REN Wei-cong, YAO Cong, GAO Fei, PANG Yu. A study of dynamic monitoring of drug sensitivity of Mycobacterium tuberculosis to bedaquiline and the mechanism of drug resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 482-486. |
[5] | SHI Zheng-yu, WU Gui-hui, HUANG Tao, LIU Yu-hong, GAO Meng-qiu, CHEN Lei, LI Xi, YANG Ming, HE Wei, CHEN Yan, LU Xiao-li, GAO Jing-tao, LI Liang. Early effectiveness and safety of bedaquiline containing regimen in treatment of multidrug-resistant and extensively drug-resistant tuberculosis: An one arm observational study of 24 weeks [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 487-494. |
[6] | GUO Hai-Ping, CHEN Lei, HUO Feng-min, PANG Yu, LI Shan-Shan. The study of in vitro synergistic activities of GSK656 with clarithromycin or azithromycin against Mycobacterium abscessus [J]. Chinese Journal of Antituberculosis, 2021, 43(2): 153-158. |
[7] | DUAN Hong-fei, CHU Nai-hui. Research progress of clinical endpoints in clinical trials of novel antituberculosis agents [J]. Chinese Journal of Antituberculosis, 2021, 43(1): 96-99. |
[8] | YANG Lu-qi, SHEN Ming-yi, SHA Wei, CHEN Ying-ying, WANG Ying. Research progress in immunoprotective mechanism of bacille Calmette-Guérin and vaccine development strategies [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 863-868. |
[9] | ZHANG Kai, SHEN Xiao-bing, TAO Li-feng, WEI Fen, CHEN Bao-wen, QIU Jing-jing, CHEN Wei, LU Jin-biao, ZHU Yin-meng, CHENG Xing, ZHONG Zai-xin, ZHAO Ai-Hua, PU Jiang. Establishment of quality standards for recombinant Mycobacterium tuberculosis fusion protein [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 814-820. |
[10] | ZHANG Kai, TAO Li-feng, WEI Fen, DU Wei-xin, QIU Jing-jing, CHEN Wei, CHEN Bao-wen, ZHU Yin-meng, CHENG Xing, SU Cheng, ZHONG Zai-xin, LU Jin-biao, PU Jiang. Immune characteristics and preclinical animal safety studies of recombinant Mycobacterium tuberculosis fusion protein(EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 807-813. |
[11] | YANG Lei, WEI Fen, ZHANG Kai, QIU Jing-jing, WANG Ying-ying, DU Wei-xin, LU Jin-biao, TAO Li-feng, PU Jiang. Stability and efficacy study of recombinant Mycobacterium tuberculosis fusion protein (EC) [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 799-806. |
[12] | SUN Qing, HUANG Hai-rong, WANG Gui-rong. In vitro activities and drug resistance mechanisms of bedaquiline, clofazimine and delamanid against common pathogenic non-tuberculous mycobacteria [J]. Chinese Journal of Antituberculosis, 2020, 42(8): 880-884. |
[13] | XIE Li, GAO Jing-tao, MA Li-ping, ZHANG Li-qun, KONG Zhong-shun, WU Xiao-guang, LIU Rong-mei, CHEN Hong-mei, SONG Yan-hua, LI Xue-lian, Huang Mai-ling, LI Qiang, Lv Zi-zheng, LIu Yv-hong, Gao Meng-qiu. Effect of bedaquiline-containing regimen on QT interval in patients with multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(7): 687-694. |
[14] | FANG Xue-e, CHEN Dan-ping, TANG Ling-ling, FAN Lin, CHEN Wei, JI Hai-ming, MAO Yan-jun. Application effect of individual case management model during the process of taking bedaquiline in patients with MDR-PTB [J]. Chinese Journal of Antituberculosis, 2020, 42(6): 641-644. |
[15] | SUN Ming-lei, GUAN Li, ZHAO Juan, WANG Chen, ZOU Dan-dan, LIANG Li-bo. Legislative considerations on traffic travel of MDR-TB/XDR-TB patients from the perspective of infectious disease prevention and control [J]. Chinese Journal of Antituberculosis, 2020, 42(12): 1268-1271. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||